Blinatumomab: An Investigational BiTE Antibody Construct Designed to Direct the Body’s Cell-destroying T-Cells Against Target Cells Expressing CD19 – Emerging Insight and Market Forecast to 2030 –

DUBLIN–(BUSINESS WIRE)–The "Blinatumomab – Emerging Insight and Market Forecast – 2030" report has been added to’s offering. Blinatumomab is an investigational BiTE antibody construct designed to direct the body’s cell-destroying T cells against target cells expressing CD19, a protein found on the surface of B-cell derived leukemias and lymphomas. Blinatumomab is the first of the BiTE antibody constructs and Amgen has received orphan drug designation from the FDA for th